Cancer genetics services: A systematic review of the economic evidence and issues

British Journal of Cancer

Volumn 90, Issue 9, 2004, Pages 1697-1703

  Griffith, G L ^a   Edwards, R T ^a   Gray, J ^b  

^a BANGOR UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Cancer; Familial; Genetic; Systematic review

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE CARRIER; ECONOMIC ASPECT; ECONOMIC EVALUATION; EXPERIMENTAL MODEL; FAMILY; FAMILY HISTORY; GENE MUTATION; GENE TECHNOLOGY; GENETIC COUNSELING; GENETIC SERVICE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; INFORMATION PROCESSING; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; SHORT SURVEY; SURVIVAL; SYSTEMATIC REVIEW;

EID: 2642567707     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601792     Document Type: Short Survey

References (54)

1. Bapat B, Noorani H, Cohen Z, Berk T, Mitri A, Gallie B, Pritzker K, Gallinger S, Detsky AS (1999) Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis. Gut 44: 698-703
2. Brain K, Gray J, Norman P, France E, Anglim C, Barton G, Parsons E, Clarke A, Sweetland H, Tischkowitz M, Myring J, Stansfield K, Webster D, Gower-Thomas K, Daoud R, Gateley C, Moneypenny I, Singhal H, Branston L, Sampson J, Roberts E, Newcombe R, Cohen D, Rogers C, Mansel R, Harper P (2000) Randomised trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst 92: 1345-1351
3. Brown ML, Kessler LG (1995) The use of gene tests to detect hereditary predisposition to cancer: economic considerations. J Natl Cancer Inst 87: 1131-1136
4. Brown ML, Kessler LG (1996) Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost-effectiveness?. Int J Cancer 69: 55-57
5. Chaliki H, Loader S, Levenkron JC, Logan-Young W, Hall WJ, Rowley PT (1995) Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 85: 1133-1135
6. Cohen D, Barton G, Gray J, Brain K. Health economics and genetic service development - a cancer genetic example (TRACE). Familial Cancer, in press
7. Couch F, De Shano M, Blackwood M, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber B (1997) BRCA1 mutation in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409-1415
8. Cromwell DM, Moore RD, Brensinger JD, Petersen GM, Bass EB, Giardiello FM (1998) Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis. Gastroenterology 114: 893-901
9. Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J (2000) Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analysis in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 36: 49-54
10. Drummond MF, O'Brien B, Stoddart GL, Torrence GW (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford University Press
11. Easton DF, Bishop DT, Ford DF, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678-701
12. Eccles DM, Englefield P, Soulby MA, Campbell IG (1998) BRCA1 mutations in Southern England. Br J Cancer 77: 2199-2203
13. Edwards RT (2001) Steering a course around the genetics iceberg. J Public Health Med 23: 3-4
14. Eeles R (1996) Testing for the breast cancer predisposition gene BRCA1. BMJ 313: 572
15. EuroQol Group (Buxton M, O'Hanlon M, Pekurinen M (1990) EuroQol: a new facility for the measurement of health related quality of life. Health Policy 16: 199-208
16. Ford D, Easton DF, Bishop DT, Norad SA, Goldgar DE (1994) Risk of cancer in BRCA1-mutation carriers. Lancet 342: 692-695
17. Ford D, Easton D R, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457-1462
18. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI (2002) Effect of prevention strategies on survival and quality adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20: 2520-2529
19. Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI (2000) Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am 6: 13-20
20. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16: 979-985
21. Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI (1999) Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 17: 494-500
22. Haggitt RC, Reid BJ (1986) Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol 10: 871-887
23. Hall J, Viney R, Haas M (1998) Taking a count: the evaluation of genetic testing. Aust N Z J Public Health 22: 754-758
24. Heimdal K, Maehle L, Moller P (1999) Costs and benefits of diagnosing familial breast cancer. Dis Markers 15: 167-173
25. HM Treasury (2003) GDP Deflators http://www.hm-treasury.gov.uk/ economic_data_and_tools/gdp_deflators/data_gdp_guide.cfm
26. King MC, Rowell S, Love SM (1993) Inherited breast and ovarian cancers, what are the risks? What are the choices? JAMA 269: 1975-1980
27. Lerman C (1997) Translational behavioural research in cancer genetics. Prev Med 26: S65-S69
28. Lidereau R, Eisinger F, Champeme M, Nogues C, Bieche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H (2000) Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 60: 1206-1210
29. Maher ER, Barton DE, Slatter R, Koch DJ, Jones MH, Nagase H, Payne SJ, Charles SJ, Moore AT, Nakamura Y, Ferguson-Smith MA (1993) Evaluation of molecular genetic diagnosis in the management of familial adenomatous polyposis coli: a population based study. J Med Genet 30: 675-678
30. Netten A, Curtis L (2003) Unit Costs of Health and Social Care. Canterbury: Personal Social services Research Unit
31. Peters JA, Biesecker BB (1997) Genetic counselling and hereditary cancer. Cancer Suppl 80: 576-586
32. Ponder BAJ (1999) Costs, benefits and limitations of genetic testing for cancer risk. Br J Cancer 80(Suppl 1): 46-50
33. Priority Areas Cancer Team/Genetics Sub-committee of the Scottish Cancer Co-ordinating and Advisory Committee (1998) Cancer Genetics Services in Scotland. Scottish Office
34. Schrag D, Kuntz KM, Garber JE, Weeks JC (2000) Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283: 617-624
35. Schrag D, Kuntz KM, Garber JE, Weeks JE (1997) Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336: 1465-1471
36. Sevilla C, Moatti JP, Julian-Reynier C, Eisinger F, Soppa-Lyonnet D, Bressac-de Paillerets B, Sobol H (2002) Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 10: 599-606
37. Soravia C, Bapat B, Cohen Z (1997) Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects. Schweiz Med Wochenschr 127: 682-690
38. Steel M, Smyth E, Vasen H, Eccles D, Evans G, Moller P, Hodgson S, Stoppa-Lyonnet D, Chang-Claude J, Caligo M, Morrison P, Haites N (1999) Ethical, social and economic issues in familial breast cancer: a compilation of views from the E.C. Biomed II Demonstration project. Dis Markers 15: 125-131
39. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Fourquet A, Salmon R, Clough K, Pouillart P, The ICBCG, Bonaiti-Pellie C, Thomas G (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Adv Hum Genet 60: 1021-1030
40. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 amongst Ashkenazi Jews. N Engl J Med 336: 1401-1408
41. Sylvester R (2000) Blair urged to rethink health funding: gene science could break the NHS. Daily Telegraph, Saturday, 8 January
42. Syngal S, Fox EA, Li C, Dovido M, Eng C, Kolonder RD, Garber JE (1999) Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 282: 247-253
43. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz K (1998) Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129: 787-796
44. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P (1995) Stage, age, comorbidity and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 87: 417-426
45. Tengs TO, Berry DA (2000) The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility gene. Dis Manage Clin Outcomes 2: 15-24
46. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA (1998) Testing for BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 18: 365-375
47. Van der Riet AAPM, Van Hout BA, Rutten FFH (1997) Cost effectiveness of DNA diagnosis for monogenic diseases. J Med Genet 34: 741-745
48. Van Orsouw NJ, Dhanda RK, Elhaji Y, Norad SA, Li FP, Eng C, Vijg J (1999) A highly accurate, low cost test for BRCA1 mutations. J Med Genet 36: 747-753
49. Vasen HFA, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34: 424-425
50. Vasen HFA, Van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, Nagengast FM, Menko FH, Khan PM (1998) A cost-effectiveness analysis of colorectal cancer screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82: 1632-1637
51. Vasen HFA, Wijnen JT, Menko FH, Kleinbeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard M-L, Mohr J, Fodde R, Klan M (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110: 1020-1027
52. Wagner JL, Tunis S, Brown M, Ching A, Almeida R (1996) Cost-effectiveness of colorectal cancer screening in average-risk adults. In Prevention and Early Detection of Colorectal Cancer, Young GP, Rosen R, Levin B (eds) pp 321-341. London: W.B. Saunders
53. Walker A, Whynes DK, Chamberlain JO, Hardcastle JD (1991) The hospital costs of diagnostic procedures for colorectal cancer. J Clin Epidemiol 44: 907-914
54. Wilson B, Ryan M, Haites N (1999) Assessing user preferences for, and costs of, genetic counselling for familial cancer risk in Scotland: a cost-utility analysis using conjoint analysis. Chief Scientist Office